Associate Professor, Department of Pharmacology and Toxicology, College of Medicine
Visit Fantegrossi’s full bio page.
Areas of Interest
Biological actions of emerging drugs of abuse, including synthetic cannabinoids (constituents of K2/ “Spice” smoking blends), analogues of cathinone (present in “bath salts” preparations), hallucinogens (related to mescaline) and novel opioids (including extremely potent fentanyl analogues.)
Selected Publications
- Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Fantegrossi WE, Wilson CD, Berquist MD. Drug Metab Rev. 50(1):65-73, 2018. PMID: 29385930
- Synthetic Pot: Not Your Grandfather’s Marijuana. Trends Pharmacol Sci. Ford BM, Tai S, Fantegrossi WE and Prather PL. 38(3):257-276, 2017. PMID: 28162792
- Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Tai S and Fantegrossi WE. Curr Top Behav Neurosci. 32:249-262, 2017. PMID: 28012093
- Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Pharmacol Res. 102:22-32, 2015. PMID: 26361728